The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The target protein corresponds to human TLR9 (UniProt Q9NR96, also designated CD289), a member of the Toll-like receptor family as specified in the provided UniProt information (karapetyan2020tolllikereceptor9 pages 4-5, behzadi2021tolllikereceptorsgeneral pages 13-14). The protein contains leucine-rich repeat (LRR) domains and a Toll/interleukin-1 receptor (TIR) domain, consistent with the supplied domain annotations (IPR001611, IPR003591, IPR041283, IPR032675, IPR000157). This confirms that the research target matches the requested gene identity.
TLR9 functions as an intracellular pattern-recognition receptor and DNA sensor that detects unmethylated cytosine-phosphate-guanosine (CpG) dinucleotide motifs, which are characteristic of bacterial, viral, fungal, and parasitic genomes (briard2020dnasensingin pages 1-3, zahid2020molecularandstructural pages 3-5). This substrate specificity enables TLR9 to distinguish microbial nucleic acids from mammalian self-DNA, wherein CpG dinucleotides are typically methylated at the cytosine residue (kumar2021thetrinityof pages 11-12, zahid2020molecularandstructural pages 3-5). TLR9 is not an enzyme and does not catalyze biochemical reactions; rather, it serves as a signaling receptor that initiates innate immune responses upon ligand recognition (bohusne2024…oftlr9mediateda pages 12-16, bohusne2024…oftlr9mediateda pages 16-20).
The substrate specificity of TLR9 extends beyond simple CpG sequence detection. Human TLR9 generally responds optimally to DNA containing two appropriately spaced CpG motifs, with a commonly cited stimulatory hexamer sequence of 5′-GTCGTT-3′ (kumar2021thetrinityof pages 11-12, karapetyan2020tolllikereceptor9 pages 4-5). This contrasts with murine TLR9, which preferentially recognizes 5′-GACGTT-3′ and can be efficiently activated by a single CpG motif positioned 4–6 nucleotides from the 5′ end (kumar2021thetrinityof pages 11-12). Recognition also depends on DNA structure, length (optimal range typically 18–29 nucleotides in experimental contexts), backbone chemistry (phosphodiester versus phosphorothioate), methylation status, and the capacity to form dimeric complexes (bohusne2024…oftlr9mediateda pages 12-16, kumar2021thetrinityof pages 11-12, bohusne2024…oftlr9mediated pages 12-16).
TLR9 can recognize various DNA sources including bacterial and viral genomes, synthetic CpG oligodeoxynucleotides (CpG-ODNs), mitochondrial DNA, and under certain conditions, nuclear self-DNA when these molecules gain access to endosomal compartments (bohusne2024…oftlr9mediateda pages 12-16, wen2023tolllikereceptors7 pages 4-5, zahid2020molecularandstructural pages 3-5). The receptor's ligands are classified into three main CpG-ODN classes (A, B, and C) that differ in structure and immunostimulatory properties (bohusne2024…oftlr9mediateda pages 16-20).
TLR9 is a type I single-pass transmembrane glycoprotein comprising three structural domains: an extracellular N-terminal ectodomain containing leucine-rich repeats (LRRs), a single transmembrane helix, and a cytoplasmic C-terminal Toll/interleukin-1 receptor (TIR) domain of approximately 150 amino acids (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5, briard2020dnasensingin pages 1-3). The extracellular region forms a horseshoe-shaped architecture containing 25–26 LRRs, each 20–43 amino acids long with a conserved "LxxLxLxxN" motif (karapetyan2020tolllikereceptor9 pages 4-5, behzadi2021tolllikereceptorsgeneral pages 13-14).
Structural studies reveal that agonistic CpG DNA functions as "molecular glue," bridging two TLR9 ectodomains to form a symmetric 2:2 receptor-ligand complex (behzadi2021tolllikereceptorsgeneral pages 13-14, tsukidate2023smallmoleculemodulators pages 6-7). The DNA contacts the N-terminal LRR region (LRRNT through LRR10) of one protomer and the C-terminal LRR region (LRR20–LRR22) of the other protomer, stabilizing receptor dimerization (behzadi2021tolllikereceptorsgeneral pages 13-14, choi2023threedimensionalmodelingof pages 4-7). This dimerization brings the cytoplasmic TIR domains into proximity, enabling recruitment of downstream signaling adaptors (zahid2020molecularandstructural pages 3-5, briard2020dnasensingin pages 1-3).
A critical regulatory feature is the Z-loop, an approximately 40-amino-acid insertion between LRR14 and LRR15 that undergoes proteolytic cleavage by endolysosomal cysteine proteases (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5). This processing generates the mature, signaling-competent form of TLR9 and represents an important safeguard against inappropriate activation by cellular DNA, as it restricts functional receptor to acidic intracellular compartments (zahid2020molecularandstructural pages 3-5, karapetyan2020tolllikereceptor9 pages 2-4).
TLR9 is synthesized, folded, and glycosylated in the endoplasmic reticulum (ER), where it initially associates with the ER membrane protein UNC93B1 (zahid2020molecularandstructural pages 3-5, behzadi2021tolllikereceptorsgeneral pages 13-14, behzadi2021tolllikereceptorsgeneral pages 8-9). Unlike cell-surface TLRs, TLR9 remains predominantly intracellular, avoiding constitutive plasma membrane exposure—though surface expression has been reported on specific cell types including neutrophils, B cells, and erythrocytes with distinct regulatory functions (kou2023surfacetolllikereceptor pages 2-3, kou2023surfacetolllikereceptor pages 5-6).
TLR9 exits the ER in COPII-positive vesicles, transits through the Golgi apparatus, and is directed toward endosomal compartments where it encounters internalized nucleic acids (kou2023surfacetolllikereceptor pages 2-3, behzadi2021tolllikereceptorsgeneral pages 8-9). This trafficking pathway depends critically on UNC93B1, which functions as a dedicated chaperone for nucleic acid-sensing TLRs (acharya2022regulatorystrategieslimiting pages 6-8, behzadi2021tolllikereceptorsgeneral pages 8-9). UNC93B1 recruits the clathrin adaptor protein complex AP-2 through a C-terminal YxxF sorting motif, facilitating TLR9 delivery to endosomes (kou2023surfacetolllikereceptor pages 2-3, acharya2022regulatorystrategieslimiting pages 6-8, song2022nglycosylationofunc93b1 pages 1-2).
Once in endosomes, TLR9 trafficking is further regulated by adaptor protein complex 3 (AP-3), which promotes progression through early endosomes, late endosomes, and ultimately LAMP2-positive lysosomal compartments (acharya2022regulatorystrategieslimiting pages 6-8, acharya2022regulatorystrategieslimiting pages 8-9). This ordered progression through distinct endosomal subcompartments determines signaling output, with early compartments favoring NF-κB-dependent inflammatory responses and later compartments supporting IRF7-dependent type I interferon production (acharya2022regulatorystrategieslimiting pages 8-9). The solute carrier SLC15A4 additionally supports proper TLR9 and ligand colocalization in specialized endolysosomal compartments, particularly in plasmacytoid dendritic cells (rimann2022thesolutecarrier pages 4-6).
A 2022 study revealed that N-glycosylation of UNC93B1 at asparagine 272 is specifically required for efficient TLR9 signaling without necessarily affecting receptor expression or localization (song2022nglycosylationofunc93b1 pages 1-2, song2022nglycosylationofunc93b1 pages 12-13). This modification enables proper MyD88 recruitment to activated TLR9 and demonstrates client-specific regulation, as the same glycosylation site is not required for TLR7 signaling (song2022nglycosylationofunc93b1 pages 1-2).
A groundbreaking 2024 Nature Communications study identified a dynamic palmitoylation cycle controlling TLR9 trafficking and activation (ni2024cyclicalpalmitoylationregulates pages 1-2, ni2024cyclicalpalmitoylationregulates pages 9-10). TLR9 undergoes S-palmitoylation at cysteine residues C258 and C265 in the ectodomain by the Golgi-localized palmitoyltransferase DHHC3 (ni2024cyclicalpalmitoylationregulates pages 1-2, ni2024cyclicalpalmitoylationregulates pages 5-5, ni2024cyclicalpalmitoylationregulates pages 6-7). This modification promotes TLR9 trafficking from the Golgi to endosomes, facilitates proteolytic cleavage, and enhances ligand binding (ni2024cyclicalpalmitoylationregulates pages 9-10, ni2024cyclicalpalmitoylationregulates pages 8-9). Subsequently, the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) removes palmitate, promoting TLR9 release from UNC93B1 and enabling productive signaling (ni2024cyclicalpalmitoylationregulates pages 1-2, ni2024cyclicalpalmitoylationregulates pages 9-10, ni2024cyclicalpalmitoylationregulates pages 7-8). Disruption of either palmitoylation or depalmitoylation impairs TLR9 function, demonstrating that the cyclical modification is essential for receptor competence (ni2024cyclicalpalmitoylationregulates pages 9-9, ni2024cyclicalpalmitoylationregulates pages 8-9).
The most recent mechanistic advance comes from a November 2025 mBio study demonstrating that TLR9 activation requires ligand-induced tyrosine phosphorylation of two specific cytoplasmic residues (veleeparambil2025tlr9signalingrequires pages 1-2, veleeparambil2025tlr9signalingrequires pages 9-11). Following CpG DNA recognition, scavenger receptor A activates the Src family kinase Lyn, which phosphorylates and activates Syk independently of TLR9 (veleeparambil2025tlr9signalingrequires pages 9-11, veleeparambil2025tlr9signalingrequires pages 7-9). Activated Syk then phosphorylates TLR9 at tyrosine 870, while constitutively TLR9-associated EGFR phosphorylates tyrosine 980 (veleeparambil2025tlr9signalingrequires pages 1-2, veleeparambil2025tlr9signalingrequires pages 9-11). Mutation of either residue completely abolishes TLR9-induced cytokine production and impairs TLR9–MyD88 interaction, establishing these phosphorylation events as obligatory for signaling (veleeparambil2025tlr9signalingrequires pages 1-2, veleeparambil2025tlr9signalingrequires pages 7-9, veleeparambil2025tlr9signalingrequires pages 11-13).
TLR9 signals exclusively through a MyD88-dependent pathway, distinguishing it from TLR3, which uses TRIF-dependent signaling (nielsen2025tlr9adoubledealing pages 1-3, zahid2020molecularandstructural pages 3-5). Upon CpG DNA binding and receptor dimerization, the TLR9 TIR domain recruits the adaptor protein MyD88, which assembles a signaling complex (the Myddosome) containing IRAK4 and IRAK1 (nielsen2025tlr9adoubledealing pages 1-3, zahid2020molecularandstructural pages 3-5). This complex recruits TRAF6 and, for interferon production, TRAF3, initiating downstream signaling cascades (bohusne2024…oftlr9mediated pages 16-20, zahid2020molecularandstructural pages 3-5).
TRAF6 activates TAK1, which feeds into two major branches. First, TAK1 phosphorylates the IKK complex, leading to IκB phosphorylation and degradation, which permits NF-κB nuclear translocation and transcription of inflammatory genes (nielsen2025tlr9adoubledealing pages 3-4, bohusne2024…oftlr9mediated pages 16-20). Second, TAK1 activates MAP kinases including p38 and JNK, culminating in AP-1 activation (nielsen2025tlr9adoubledealing pages 3-4, wen2023tolllikereceptors7 pages 4-5). These pathways drive production of proinflammatory cytokines including TNF-α, IL-6, IL-1β, IL-8, IL-12, and various chemokines (nielsen2025tlr9adoubledealing pages 3-4, bohusne2024…oftlr9mediated pages 16-20, bohusne2024…oftlr9mediateda pages 16-20).
In plasmacytoid dendritic cells, TLR9 activation produces robust type I interferon responses through a TRAF3/IKKα/IRF7 axis (briard2020dnasensingin pages 1-3, zahid2020molecularandstructural pages 3-5). This response is particularly strong when CpG DNA reaches specialized IRF-signaling endolysosomal compartments and generates large amounts of IFN-α and IFN-β (bohusne2024…oftlr9mediated pages 16-20, bohusne2024…oftlr9mediateda pages 16-20, acharya2022regulatorystrategieslimiting pages 8-9). The balance between NF-κB-driven inflammatory cytokine production and IRF7-driven interferon production depends on endosomal compartmentalization, with AP-3-mediated trafficking promoting the transition from early NF-κB to later IRF7 signaling (acharya2022regulatorystrategieslimiting pages 8-9).
TLR9 expression and signaling outcomes vary by cell type. It is prominently expressed in plasmacytoid dendritic cells (pDCs), where it drives type I interferon production; in B cells, where it promotes proliferation, differentiation, antibody production, and class switching; and in various other immune and non-immune cell types including macrophages, conventional dendritic cells, and some epithelial cells (wen2023tolllikereceptors7 pages 4-5).
TLR9 agonists have emerged as promising cancer immunotherapeutics, primarily in combination with immune checkpoint inhibitors (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 16-18, rolfo2023applicationsandclinical pages 1-2). The therapeutic rationale centers on activating plasmacytoid dendritic cells, natural killer cells, and T cells to overcome tumor immunosuppression and convert immunologically "cold" tumors into "hot" tumors responsive to checkpoint blockade (nielsen2025tlr9adoubledealing pages 16-18, rolfo2023applicationsandclinical pages 1-2).
| TLR9 agonist | Form / mechanism | Cancer setting(s) | Trial phase / status reported | Combination or delivery strategy | Clinical-trial identifier(s) | Reported efficacy | Interpretation | Sources |
|---|---|---|---|---|---|---|---|---|
| SD-101 | Synthetic class C CpG oligodeoxynucleotide | Metastatic melanoma; lymphoma; pancreatic, prostate, liver, and breast cancers; other solid tumors | Phase I/II studies; completed phase II studies also reported | Pembrolizumab in melanoma; radiotherapy in lymphoma and prostate cancer; other drug combinations | NCT04050085 (pancreatic), NCT03007732 (prostate), NCT05220722 (liver), NCT01042379 (breast), NCT02254772 and NCT03322384 (solid tumors/lymphoma) | SD-101 plus pembrolizumab produced responses in 7/9 (78%) PD-1-inhibitor-naïve melanoma patients in a small study; broader results have varied | Illustrates the leading strategy of local TLR9 activation combined with checkpoint blockade or radiation; the 78% estimate is based on only nine patients and should not be generalized | (nielsen2025tlr9adoubledealing pages 15-16, mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23) |
| CMP-001 (vidutolimod) | CpG-A-rich DNA packaged for uptake by plasmacytoid dendritic cells, driving IRF7 and IFN-α | Melanoma; lung carcinoma; triple-negative breast cancer; other checkpoint-refractory tumors | Phase II melanoma evidence; multiple phase I/II or perioperative studies listed | Nivolumab or pembrolizumab; radiotherapy; surgery and systemic therapy | NCT03438318 (lung/radiotherapy), NCT04807192 (triple-negative breast cancer/radiotherapy), NCT04401995, NCT04708418, NCT04698187, NCT03618641 (melanoma programs) | CMP-001 plus nivolumab achieved an objective response rate (ORR) of 45% (14/31) in one phase II melanoma study | Promising combination signal, but efficacy depends on functional plasmacytoid dendritic cells, antigen presentation, and an intact type-I-interferon response | (nielsen2025tlr9adoubledealing pages 9-11, mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23, nielsen2025tlr9adoubledealing pages 16-18) |
| MGN1703 (lefitolimod) | Covalently closed dumbbell-shaped DNA TLR9 agonist | Metastatic colorectal cancer; extensive-stage small-cell lung cancer | Clinical maintenance studies; phase not specified in the gathered excerpts | Primarily maintenance monotherapy; combination development also discussed | Not specified in the gathered evidence | 7% ORR in metastatic colorectal cancer, with significant progression-free-survival improvement versus placebo; progression-free-survival benefit was not reproduced in extensive-stage small-cell lung cancer | Demonstrates that pharmacodynamic immune activation or benefit in one tumor type may not translate across indications | (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 9-11) |
| IMO-2125 (tilsotolimod) | Synthetic TLR9-targeting oligonucleotide | Checkpoint-refractory solid tumors; melanoma and other solid carcinomas | Early-phase and phase II programs reported | Tested alone and with other anticancer drugs or checkpoint-directed therapy | NCT03865082 (solid carcinomas), NCT04126876 (melanoma) | 0% ORR in the cited refractory-solid-tumor cohort despite increased immune activation in tumor biopsies | A key negative translational example: target engagement did not yield objective tumor regression in the reported cohort | (nielsen2025tlr9adoubledealing pages 9-11, mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23) |
| AST-008 (cavrotolimod) | Spherical nucleic-acid TLR9 agonist designed to improve cellular delivery | Refractory advanced skin cancers | Early clinical combination study; exact phase not specified in the gathered excerpt | Combined with anti-PD-1 therapy | Not specified in the gathered evidence | 11.7% ORR (6/51) | Targeted formulation and checkpoint combination produced activity in a minority of heavily pretreated patients, underscoring both feasibility and limited overall response | (nielsen2025tlr9adoubledealing pages 15-16) |
| TAC-001 | Targeted CpG conjugate described as an anti-CD22–CpG platform | Checkpoint-refractory advanced or metastatic solid tumors | Ongoing phase I/II study | Antibody-mediated targeted delivery of a TLR9 agonist | Not specified in the gathered evidence | 2.9% ORR (2/69) | Precision delivery may reduce nonspecific exposure, but the reported objective-response rate was low; platform identity and target expression should be confirmed for the specific trial cohort | (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 9-11) |
Table: Clinical and translational landscape of selected TLR9 agonists summarized from 2023–2025 sources, including combination strategies, trial identifiers, and reported response rates. Results remain heterogeneous, with the strongest signals generally arising from small checkpoint-inhibitor combination cohorts.
Key clinical findings include:
SD-101, a class C CpG oligonucleotide, achieved a 78% objective response rate (7/9 patients) when combined with pembrolizumab in PD-1-inhibitor-naïve melanoma patients, compared to typical 35-40% response rates for pembrolizumab alone (nielsen2025tlr9adoubledealing pages 15-16). Multiple phase I/II trials are evaluating SD-101 in pancreatic cancer (NCT04050085), prostate cancer (NCT03007732), liver cancer (NCT05220722), and breast cancer (NCT01042379).
CMP-001 (vidutolimod), a CpG-A agonist packaged to target plasmacytoid dendritic cells, produced a 45% objective response rate (14/31 patients) when combined with nivolumab in phase II melanoma studies (nielsen2025tlr9adoubledealing pages 9-11). The agent is being evaluated with radiotherapy in lung cancer (NCT03438318) and triple-negative breast cancer (NCT04807192), as well as in multiple melanoma combination trials (mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23).
MGN1703 demonstrated a 7% objective response rate in metastatic colorectal cancer with significant progression-free survival improvement versus placebo, though this benefit was not reproduced in small-cell lung cancer (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 9-11).
However, not all TLR9 agonist trials have succeeded. IMO-2125 (tilsotolimod) produced 0% objective responses in refractory solid tumors despite increased immune activation in biopsies, illustrating that target engagement does not always translate to clinical benefit (nielsen2025tlr9adoubledealing pages 9-11, mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23).
Current therapeutic development emphasizes combination approaches. Class A and C CpG oligodeoxynucleotides show particular promise with immune checkpoint inhibitors, while class B agonists may be more suitable for cancer vaccine adjuvants (nielsen2025tlr9adoubledealing pages 16-18). Clinical efficacy depends on functional plasmacytoid dendritic cells, intact antigen presentation, and an effective type I interferon response within the tumor microenvironment (nielsen2025tlr9adoubledealing pages 16-18, chakraborty2023applicationoftolllike pages 8-9).
Novel precision-delivery strategies are being developed to improve TLR9 agonist efficacy and reduce systemic toxicity. AST-008 (cavrotolimod), a spherical nucleic acid formulation combined with anti-PD-1 therapy, achieved an 11.7% objective response rate (6/51 patients) in refractory advanced skin cancers (nielsen2025tlr9adoubledealing pages 15-16). TAC-001, an anti-CD22-CpG conjugate, produced a 2.9% objective response rate (2/69 patients) in checkpoint-refractory solid tumors, demonstrating feasibility of antibody-mediated targeted delivery (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 9-11).
A paradigm-shifting 2024 Nature study revealed that TLR9 plays an unexpected role in memory formation through a DNA-damage-sensing and repair pathway in hippocampal neurons (jovasevic2024formationofmemory pages 1-2). Following contextual fear conditioning, discrete clusters of excitatory CA1 neurons developed persistent double-stranded DNA breaks, nuclear envelope ruptures, and perinuclear DNA fragment release. These neurons subsequently activated TLR9 signaling, which contributed to centrosome function, DNA damage repair, ciliogenesis, and formation of perineuronal nets—structures that stabilize memory circuits (jovasevic2024formationofmemory pages 1-2). Neuron-specific Tlr9 knockdown impaired memory formation and reduced conditioning-induced gene expression changes, demonstrating that TLR9 helps recruit DNA-damaged-but-repaired neurons into memory assemblies. This discovery suggests that compromised TLR9 function may contribute to cognitive impairments in aging, psychiatric disorders, and neurodegeneration (jovasevic2024formationofmemory pages 1-2).
Beyond classical innate immunity, TLR9 exhibits diverse regulatory roles. Surface TLR9 on neutrophils functions as an immune checkpoint, with sTLR9-positive neutrophils showing immunosuppressive characteristics including PD-L1 expression, IL-10 production, and reduced inflammatory responses (kou2023surfacetolllikereceptor pages 5-6). In B cells, TLR9 contributes to immune tolerance and can suppress inappropriate autoantibody formation while promoting germinal center responses, affinity maturation, and memory antibody production (wen2023tolllikereceptors7 pages 4-5). Erythrocyte surface TLR9 binds circulating CpG DNA, promoting macrophage-mediated clearance that removes inflammatory stimuli but may contribute to inflammation-associated anemia (kou2023surfacetolllikereceptor pages 5-6).
The field has witnessed extraordinary progress in understanding TLR9 regulation, with the 2022-2025 period yielding fundamental insights into UNC93B1 glycosylation, cyclical palmitoylation, and tyrosine phosphorylation mechanisms that control receptor trafficking and activation (song2022nglycosylationofunc93b1 pages 1-2, ni2024cyclicalpalmitoylationregulates pages 1-2, veleeparambil2025tlr9signalingrequires pages 1-2). These discoveries reveal TLR9 regulation as a multi-layered process involving protein-protein interactions, post-translational modifications, and spatiotemporal compartmentalization.
In cancer immunotherapy, TLR9 agonists represent a promising but challenging translational frontier. Success depends on appropriate patient selection (functional pDCs, intact interferon responses), optimal ligand class selection, effective delivery strategies, and rational combinations with checkpoint inhibitors or radiotherapy (nielsen2025tlr9adoubledealing pages 15-16, nielsen2025tlr9adoubledealing pages 16-18). The heterogeneous clinical results—ranging from 0% to 78% response rates—underscore the complexity of converting innate immune activation into durable antitumor responses.
The discovery of TLR9's role in neuronal DNA damage repair and memory formation opens entirely new research directions, suggesting potential applications in cognitive disorders and neurodegenerative diseases beyond its established immunological functions (jovasevic2024formationofmemory pages 1-2).
| Feature | Structural or functional annotation | Human–mouse distinction / evidence note | Sources |
|---|---|---|---|
| Identity and receptor class | TLR9 (CD289; UniProt Q9NR96) is a type-I single-pass transmembrane glycoprotein and intracellular pattern-recognition receptor in the Toll-like receptor family. It is a signaling receptor, not an enzyme or transporter. | The requested identity is human TLR9; mechanistic findings from mouse systems are identified separately below. | (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5) |
| Overall architecture | An N-terminal luminal ectodomain is followed by one transmembrane helix and a cytoplasmic C-terminal Toll/interleukin-1 receptor (TIR) domain of approximately 150 residues. | This architecture is conserved across mammalian TLR9 orthologs. | (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5) |
| Leucine-rich-repeat ectodomain | The horseshoe-shaped ectodomain contains approximately 25–26 leucine-rich repeats (LRRs); differing counts reflect annotation conventions. The LRR surface binds DNA and supports ligand-dependent receptor assembly. | The LRR architecture agrees with the supplied InterPro annotations: Leu-rich repeats, typical LRR subtype, LRR_12, and LRR superfamily. | (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5, behzadi2021tolllikereceptorsgeneral pages 13-14) |
| Z-loop and proteolytic maturation | An inserted Z-loop between LRR14 and LRR15 is cleaved by endolysosomal proteases. Proteolytic processing generates signaling-competent TLR9 and helps restrict activation to acidic intracellular compartments. | Demonstrated extensively in mammalian experimental systems; cleavage is a key safeguard against inappropriate recognition of cellular DNA. | (karapetyan2020tolllikereceptor9 pages 4-5, zahid2020molecularandstructural pages 3-5) |
| TIR signaling domain | Ligand-induced receptor assembly brings cytoplasmic TIR domains together, permitting recruitment of the adaptor MyD88 and formation of the downstream signalosome. | The TIR domain is consistent with the supplied IPR000157 annotation. | (zahid2020molecularandstructural pages 3-5, briard2020dnasensingin pages 1-3) |
| Primary ligand | TLR9 preferentially recognizes DNA containing unmethylated CpG dinucleotides, which are enriched in many bacterial and viral genomes relative to vertebrate nuclear DNA. It can also respond to appropriately delivered mitochondrial or nuclear self-DNA. | CpG methylation is an important but incomplete self/non-self discriminator; sequence, length, backbone chemistry, structure, uptake, nuclease processing, and endosomal delivery also determine activity. | (kumar2021thetrinityof pages 11-12, briard2020dnasensingin pages 1-3, zahid2020molecularandstructural pages 3-5) |
| Human ligand preference | A commonly reported optimal human stimulatory hexamer is 5′-GTCGTT-3′. Human TLR9 generally responds best when two CpG motifs are positioned appropriately within an oligonucleotide. | Human sequence preferences must not be inferred directly from mouse CpG-ODN studies. | (kumar2021thetrinityof pages 11-12, karapetyan2020tolllikereceptor9 pages 4-5) |
| Mouse ligand preference | A commonly reported murine stimulatory hexamer is 5′-GACGTT-3′; mouse TLR9 can be activated efficiently by a single CpG motif located approximately 4–6 nucleotides from the 5′ end in some experimental contexts. | This species difference explains why mouse CpG reagents such as ODN1826 are not automatically optimal for human TLR9. | (kumar2021thetrinityof pages 11-12, karapetyan2020tolllikereceptor9 pages 4-5) |
| DNA-binding mechanism | Agonistic DNA bridges two ectodomains in a symmetric 2:2 TLR9–DNA complex. DNA contacts the N-terminal LRR region of one protomer and C-terminal LRRs of the other, functioning as molecular glue that stabilizes the active dimer. | Structural descriptions derive largely from crystallographic and biochemical studies of mammalian TLR9 ectodomains. | (behzadi2021tolllikereceptorsgeneral pages 13-14, tsukidate2023smallmoleculemodulators pages 6-7) |
| Resting localization | Newly synthesized TLR9 is folded, glycosylated, and retained initially in the endoplasmic reticulum (ER) rather than being constitutively exposed at the cell surface. | Surface TLR9 has nevertheless been reported on selected cells, including neutrophils, B cells, and erythrocytes; this is distinct from canonical signaling by endosomal TLR9. | (kou2023surfacetolllikereceptor pages 2-3, behzadi2021tolllikereceptorsgeneral pages 8-9, kou2023surfacetolllikereceptor pages 5-6) |
| Secretory-pathway transit | TLR9 exits the ER in COPII-positive vesicles, transits the Golgi, and is sorted toward endosomal compartments. | TMED2, gp96, PRAT4A, and other biosynthetic factors can contribute, but UNC93B1 is the central dedicated trafficking chaperone. | (kou2023surfacetolllikereceptor pages 2-3, behzadi2021tolllikereceptorsgeneral pages 8-9) |
| Functional localization | DNA recognition and canonical signaling occur primarily in acidified endosomes and endolysosomes/lysosomes, where ligand processing and TLR9 proteolytic maturation take place. | Spatial restriction reduces inappropriate activation by abundant extracellular or intracellular self-DNA. | (zahid2020molecularandstructural pages 3-5, acharya2022regulatorystrategieslimiting pages 6-8, rimann2022thesolutecarrier pages 4-6) |
| UNC93B1 | UNC93B1 binds TLR9 in the ER, enables ER exit and endosomal delivery, and is released from TLR9 in endolysosomes before productive signaling. UNC93B1 glycosylation at Asn272 is required for efficient TLR9–MyD88 recruitment without necessarily changing receptor localization. | The Asn272 glycosylation requirement was selective for TLR9 over TLR7 in the cited 2022 study. | (acharya2022regulatorystrategieslimiting pages 6-8, song2022nglycosylationofunc93b1 pages 1-2) |
| AP-2 | UNC93B1 recruits the clathrin adaptor AP-2 through a C-terminal YxxF sorting motif, supporting internalization and delivery of TLR9 to endosomes. | Much of the detailed genetic evidence comes from murine macrophage and dendritic-cell systems. | (kou2023surfacetolllikereceptor pages 2-3, acharya2022regulatorystrategieslimiting pages 6-8, song2022nglycosylationofunc93b1 pages 1-2) |
| AP-3 | AP-3 promotes progression from early endosomes through late endosomes to LAMP2-positive lysosomal compartments and helps switch output from early NF-κB signaling toward later IRF7/type-I-interferon signaling. | Loss of AP-3 can reduce interferon production while increasing inflammatory-cytokine-biased signaling. | (acharya2022regulatorystrategieslimiting pages 6-8, acharya2022regulatorystrategieslimiting pages 8-9) |
| SLC15A4 | SLC15A4 supports delivery or retention of TLR9 and CpG ligand in specialized LAMP2-positive endolysosomal compartments, especially in plasmacytoid dendritic cells. | Loss-of-function reduces receptor–ligand colocalization and TLR9 responses without necessarily abolishing receptor cleavage. | (rimann2022thesolutecarrier pages 4-6) |
| S-palmitoylation | A 2024 study mapped murine TLR9 S-palmitoylation to C258 and C265 in an ectodomain loop. Golgi-localized DHHC3 promotes palmitoylation, facilitating Golgi-to-endosome trafficking, cleavage, ligand binding, and signaling. Human TLR9 was also shown to be palmitoylated. | C258/C265 are experimentally mapped murine sites; equivalent site-specific assignment in endogenous human TLR9 should not be assumed without direct confirmation. | (ni2024cyclicalpalmitoylationregulates pages 1-2, ni2024cyclicalpalmitoylationregulates pages 9-10, ni2024cyclicalpalmitoylationregulates pages 5-5) |
| Depalmitoylation | Lysosomal PPT1 removes palmitate after endosomal delivery, promoting release of TLR9 from UNC93B1. Blocking either palmitoylation or depalmitoylation diminishes productive signaling. | PPT1 inhibition reduced IFN-α from human and mouse plasmacytoid dendritic cells ex vivo, whereas lupus-disease improvement was demonstrated in mice. | (ni2024cyclicalpalmitoylationregulates pages 1-2, ni2024cyclicalpalmitoylationregulates pages 9-10, ni2024cyclicalpalmitoylationregulates pages 7-8) |
| Tyrosine phosphorylation | A 2025 study reported sequential phosphorylation of cytoplasmic Y870 by Syk and Y980 by EGFR. Mutation of either site abolished cytokine induction and impaired TLR9–MyD88 coupling. Upstream scavenger receptor A activates Lyn and then Syk. | This is a recent mechanistic extension beyond the established canonical model and should be interpreted in the studied cellular systems pending broader validation in primary human cells. | (veleeparambil2025tlr9signalingrequires pages 1-2, veleeparambil2025tlr9signalingrequires pages 9-11, veleeparambil2025tlr9signalingrequires pages 7-9) |
| MyD88 and IRAKs | Activated TLR9 recruits MyD88, which assembles a Myddosome containing IRAK4 and IRAK1. This is the obligatory core of canonical TLR9 signaling. | Unlike TLR3, TLR9 is principally MyD88-dependent rather than TRIF-dependent. | (nielsen2025tlr9adoubledealing pages 1-3, zahid2020molecularandstructural pages 3-5) |
| TRAF and TAK1 branch | IRAK activation recruits TRAF6 and, for interferon-associated signaling, TRAF3. TRAF6 activates TAK1, which feeds into NF-κB and MAPK pathways. | Output depends on cell type and endosomal compartment. | (bohusne2024…oftlr9mediated pages 16-20, zahid2020molecularandstructural pages 3-5) |
| NF-κB and MAPK/AP-1 outputs | TAK1 activates the IKK–IκB–NF-κB axis and MAPKs including p38/JNK, culminating in AP-1 activation and transcription of inflammatory mediators such as TNF, IL-6, IL-1-family cytokines, IL-12, and chemokines. | Cytokine composition varies by ligand class, cell type, dose, and trafficking route. | (nielsen2025tlr9adoubledealing pages 3-4, bohusne2024…oftlr9mediated pages 16-20, wen2023tolllikereceptors7 pages 4-5) |
| IRF7/type-I-interferon output | In plasmacytoid dendritic cells, a TRAF3/IKKα-associated branch activates IRF7, producing large amounts of type-I interferon, especially IFN-α. | This response is strongest when ligand reaches the appropriate IRF-signaling endolysosomal compartment; other compartments favor NF-κB-biased output. | (briard2020dnasensingin pages 1-3, zahid2020molecularandstructural pages 3-5, acharya2022regulatorystrategieslimiting pages 8-9) |
Table: This table integrates human TLR9 identity, architecture, CpG-DNA specificity, intracellular trafficking, post-translational control, and canonical signaling. It also separates human-specific conclusions from findings established mainly in mouse experimental systems.
TLR9 functions as a sophisticated intracellular DNA sensor that recognizes unmethylated CpG motifs to initiate innate immune responses through MyD88-dependent signaling pathways. The receptor operates primarily in acidified endosomal and lysosomal compartments, where it undergoes proteolytic maturation and recognizes internalized nucleic acids. Recent discoveries have revealed elaborate regulation through cyclical palmitoylation, site-specific glycosylation of trafficking chaperones, and ligand-induced tyrosine phosphorylation, representing major advances in our understanding of receptor activation mechanisms.
TLR9 activation drives NF-κB, MAPK, and IRF7 pathways, producing inflammatory cytokines and type I interferons in a compartment- and cell-type-specific manner. Current therapeutic applications focus on synthetic CpG oligodeoxynucleotides as cancer immunotherapy agents, with multiple ongoing clinical trials evaluating combinations with checkpoint inhibitors, radiotherapy, and targeted delivery strategies. The recent identification of TLR9's role in neuronal memory formation adds an unexpected dimension to its biological functions, extending its relevance beyond classical immunology into neuroscience and cognitive health.
References
(karapetyan2020tolllikereceptor9 pages 4-5): Lilit Karapetyan, Jason J Luke, and Diwakar Davar. Toll-like receptor 9 agonists in cancer. OncoTargets and therapy, 13:10039-10060, Oct 2020. URL: https://doi.org/10.2147/ott.s247050, doi:10.2147/ott.s247050. This article has 161 citations.
(behzadi2021tolllikereceptorsgeneral pages 13-14): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(briard2020dnasensingin pages 1-3): Benoit Briard, David E. Place, and Thirumala-Devi Kanneganti. Dna sensing in the innate immune response. Physiology, 35 2:112-124, Mar 2020. URL: https://doi.org/10.1152/physiol.00022.2019, doi:10.1152/physiol.00022.2019. This article has 281 citations and is from a peer-reviewed journal.
(zahid2020molecularandstructural pages 3-5): Ayesha Zahid, Hazrat Ismail, Bofeng Li, and Tengchuan Jin. Molecular and structural basis of dna sensors in antiviral innate immunity. Frontiers in Immunology, Nov 2020. URL: https://doi.org/10.3389/fimmu.2020.613039, doi:10.3389/fimmu.2020.613039. This article has 125 citations and is from a peer-reviewed journal.
(kumar2021thetrinityof pages 11-12): Vijay Kumar. The trinity of cgas, tlr9, and alrs guardians of the cellular galaxy against host-derived self-dna. Frontiers in Immunology, Feb 2021. URL: https://doi.org/10.3389/fimmu.2020.624597, doi:10.3389/fimmu.2020.624597. This article has 125 citations and is from a peer-reviewed journal.
(bohusne2024…oftlr9mediateda pages 12-16): BBA Bohusné. … of tlr9-mediated autophagy response and growth factor signaling inhibition in colon adenocarcinoma cells: cell-free dna …. Unknown journal, 2024.
(bohusne2024…oftlr9mediateda pages 16-20): BBA Bohusné. … of tlr9-mediated autophagy response and growth factor signaling inhibition in colon adenocarcinoma cells: cell-free dna …. Unknown journal, 2024.
(bohusne2024…oftlr9mediated pages 12-16): BBA Bohusné. … of tlr9-mediated autophagy response and growth factor signaling inhibition in colon adenocarcinoma cells: cell-free dna …. Unknown journal, 2024.
(wen2023tolllikereceptors7 pages 4-5): Luyao Wen, Bei Zhang, Xinfeng Wu, Rongzeng Liu, Hua Fan, Lei Han, Zhibo Zhang, Xin Ma, Cong-Qiu Chu, and Xiaofei Shi. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of b cells in systemic lupus erythematosus. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1093208, doi:10.3389/fimmu.2023.1093208. This article has 73 citations and is from a peer-reviewed journal.
(tsukidate2023smallmoleculemodulators pages 6-7): Taku Tsukidate, Charles W. Hespen, and Howard C. Hang. Small molecule modulators of immune pattern recognition receptors. RSC Chemical Biology, 4:1014-1036, Oct 2023. URL: https://doi.org/10.1039/d3cb00096f, doi:10.1039/d3cb00096f. This article has 23 citations and is from a peer-reviewed journal.
(choi2023threedimensionalmodelingof pages 4-7): Tansol Choi, George Maiti, and Shukti Chakravarti. Three-dimensional modeling of cpg dna binding with matrix lumican shows leucine-rich repeat motif involvement as in tlr9-cpg dna interactions. International Journal of Molecular Sciences, 24:14990, Oct 2023. URL: https://doi.org/10.3390/ijms241914990, doi:10.3390/ijms241914990. This article has 6 citations.
(karapetyan2020tolllikereceptor9 pages 2-4): Lilit Karapetyan, Jason J Luke, and Diwakar Davar. Toll-like receptor 9 agonists in cancer. OncoTargets and therapy, 13:10039-10060, Oct 2020. URL: https://doi.org/10.2147/ott.s247050, doi:10.2147/ott.s247050. This article has 161 citations.
(behzadi2021tolllikereceptorsgeneral pages 8-9): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(kou2023surfacetolllikereceptor pages 2-3): Mengyuan Kou and Liying Wang. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect. Frontiers in Immunology, Sep 2023. URL: https://doi.org/10.3389/fimmu.2023.1259989, doi:10.3389/fimmu.2023.1259989. This article has 68 citations and is from a peer-reviewed journal.
(kou2023surfacetolllikereceptor pages 5-6): Mengyuan Kou and Liying Wang. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect. Frontiers in Immunology, Sep 2023. URL: https://doi.org/10.3389/fimmu.2023.1259989, doi:10.3389/fimmu.2023.1259989. This article has 68 citations and is from a peer-reviewed journal.
(acharya2022regulatorystrategieslimiting pages 6-8): Mridu Acharya and Shaun W. Jackson. Regulatory strategies limiting endosomal toll‐like receptor activation in b cells *. Immunological Reviews, 307:66-78, Jan 2022. URL: https://doi.org/10.1111/imr.13065, doi:10.1111/imr.13065. This article has 9 citations and is from a domain leading peer-reviewed journal.
(song2022nglycosylationofunc93b1 pages 1-2): Hyun-Sup Song, Soeun Park, Ji-Won Huh, Yu-Ran Lee, Da-Jung Jung, Chorong Yang, So Hyun Kim, Ho Min Kim, and You-Me Kim. N-glycosylation of unc93b1 at a specific asparagine residue is required for tlr9 signaling. Frontiers in Immunology, Jul 2022. URL: https://doi.org/10.3389/fimmu.2022.875083, doi:10.3389/fimmu.2022.875083. This article has 6 citations and is from a peer-reviewed journal.
(acharya2022regulatorystrategieslimiting pages 8-9): Mridu Acharya and Shaun W. Jackson. Regulatory strategies limiting endosomal toll‐like receptor activation in b cells *. Immunological Reviews, 307:66-78, Jan 2022. URL: https://doi.org/10.1111/imr.13065, doi:10.1111/imr.13065. This article has 9 citations and is from a domain leading peer-reviewed journal.
(rimann2022thesolutecarrier pages 4-6): Ivo Rimann, Rosana Gonzalez-Quintial, Roberto Baccala, William B. Kiosses, John R. Teijaro, Christopher G. Parker, Xiaohong Li, Bruce Beutler, Dwight H. Kono, and Argyrios N. Theofilopoulos. The solute carrier slc15a4 is required for optimal trafficking of nucleic acid–sensing tlrs and ligands to endolysosomes. Proceedings of the National Academy of Sciences of the United States of America, Mar 2022. URL: https://doi.org/10.1073/pnas.2200544119, doi:10.1073/pnas.2200544119. This article has 45 citations and is from a highest quality peer-reviewed journal.
(song2022nglycosylationofunc93b1 pages 12-13): Hyun-Sup Song, Soeun Park, Ji-Won Huh, Yu-Ran Lee, Da-Jung Jung, Chorong Yang, So Hyun Kim, Ho Min Kim, and You-Me Kim. N-glycosylation of unc93b1 at a specific asparagine residue is required for tlr9 signaling. Frontiers in Immunology, Jul 2022. URL: https://doi.org/10.3389/fimmu.2022.875083, doi:10.3389/fimmu.2022.875083. This article has 6 citations and is from a peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 1-2): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 9-10): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 5-5): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 6-7): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 8-9): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 7-8): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(ni2024cyclicalpalmitoylationregulates pages 9-9): Hai Ni, Yinuo Wang, Kai Yao, Ling Wang, Jiancheng Huang, Yongfang Xiao, Hongyao Chen, Bo Liu, Cliff Y. Yang, and Jijun Zhao. Cyclical palmitoylation regulates tlr9 signalling and systemic autoimmunity in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-43650-z, doi:10.1038/s41467-023-43650-z. This article has 133 citations and is from a highest quality peer-reviewed journal.
(veleeparambil2025tlr9signalingrequires pages 1-2): Manoj Veleeparambil, Chenyao Wang, Patricia M. Kessler, Pracheta Sengupta, Santanu Das, Ritu Chakravarti, Belinda Willard, Ganes C. Sen, and Saurabh Chattopadhyay. Tlr9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by egfr and syk. mBio, Nov 2025. URL: https://doi.org/10.1128/mbio.00276-25, doi:10.1128/mbio.00276-25. This article has 6 citations and is from a domain leading peer-reviewed journal.
(veleeparambil2025tlr9signalingrequires pages 9-11): Manoj Veleeparambil, Chenyao Wang, Patricia M. Kessler, Pracheta Sengupta, Santanu Das, Ritu Chakravarti, Belinda Willard, Ganes C. Sen, and Saurabh Chattopadhyay. Tlr9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by egfr and syk. mBio, Nov 2025. URL: https://doi.org/10.1128/mbio.00276-25, doi:10.1128/mbio.00276-25. This article has 6 citations and is from a domain leading peer-reviewed journal.
(veleeparambil2025tlr9signalingrequires pages 7-9): Manoj Veleeparambil, Chenyao Wang, Patricia M. Kessler, Pracheta Sengupta, Santanu Das, Ritu Chakravarti, Belinda Willard, Ganes C. Sen, and Saurabh Chattopadhyay. Tlr9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by egfr and syk. mBio, Nov 2025. URL: https://doi.org/10.1128/mbio.00276-25, doi:10.1128/mbio.00276-25. This article has 6 citations and is from a domain leading peer-reviewed journal.
(veleeparambil2025tlr9signalingrequires pages 11-13): Manoj Veleeparambil, Chenyao Wang, Patricia M. Kessler, Pracheta Sengupta, Santanu Das, Ritu Chakravarti, Belinda Willard, Ganes C. Sen, and Saurabh Chattopadhyay. Tlr9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by egfr and syk. mBio, Nov 2025. URL: https://doi.org/10.1128/mbio.00276-25, doi:10.1128/mbio.00276-25. This article has 6 citations and is from a domain leading peer-reviewed journal.
(nielsen2025tlr9adoubledealing pages 1-3): Megan Nielsen, Daisuke Nishizaki, Shumei Kato, and Razelle Kurzrock. Tlr9: a double-dealing toll-like receptor. ImmunoTargets and Therapy, Volume 14:1531-1554, Dec 2025. URL: https://doi.org/10.2147/itt.s563765, doi:10.2147/itt.s563765. This article has 7 citations.
(bohusne2024…oftlr9mediated pages 16-20): BBA Bohusné. … of tlr9-mediated autophagy response and growth factor signaling inhibition in colon adenocarcinoma cells: cell-free dna …. Unknown journal, 2024.
(nielsen2025tlr9adoubledealing pages 3-4): Megan Nielsen, Daisuke Nishizaki, Shumei Kato, and Razelle Kurzrock. Tlr9: a double-dealing toll-like receptor. ImmunoTargets and Therapy, Volume 14:1531-1554, Dec 2025. URL: https://doi.org/10.2147/itt.s563765, doi:10.2147/itt.s563765. This article has 7 citations.
(nielsen2025tlr9adoubledealing pages 15-16): Megan Nielsen, Daisuke Nishizaki, Shumei Kato, and Razelle Kurzrock. Tlr9: a double-dealing toll-like receptor. ImmunoTargets and Therapy, Volume 14:1531-1554, Dec 2025. URL: https://doi.org/10.2147/itt.s563765, doi:10.2147/itt.s563765. This article has 7 citations.
(nielsen2025tlr9adoubledealing pages 16-18): Megan Nielsen, Daisuke Nishizaki, Shumei Kato, and Razelle Kurzrock. Tlr9: a double-dealing toll-like receptor. ImmunoTargets and Therapy, Volume 14:1531-1554, Dec 2025. URL: https://doi.org/10.2147/itt.s563765, doi:10.2147/itt.s563765. This article has 7 citations.
(rolfo2023applicationsandclinical pages 1-2): Christian Rolfo, Elisa Giovannetti, Pablo Martinez, Shannon McCue, and Aung Naing. Applications and clinical trial landscape using toll-like receptor agonists to reduce the toll of cancer. NPJ Precision Oncology, Mar 2023. URL: https://doi.org/10.1038/s41698-023-00364-1, doi:10.1038/s41698-023-00364-1. This article has 193 citations and is from a peer-reviewed journal.
(mukherjee2023tolllikereceptorguidedtherapeutic pages 21-23): Suprabhat Mukherjee, Ritwik Patra, Payam Behzadi, Andrea Masotti, Alessandro Paolini, and Meysam Sarshar. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives. Frontiers in Immunology, Sep 2023. URL: https://doi.org/10.3389/fimmu.2023.1244345, doi:10.3389/fimmu.2023.1244345. This article has 167 citations and is from a peer-reviewed journal.
(nielsen2025tlr9adoubledealing pages 9-11): Megan Nielsen, Daisuke Nishizaki, Shumei Kato, and Razelle Kurzrock. Tlr9: a double-dealing toll-like receptor. ImmunoTargets and Therapy, Volume 14:1531-1554, Dec 2025. URL: https://doi.org/10.2147/itt.s563765, doi:10.2147/itt.s563765. This article has 7 citations.
(chakraborty2023applicationoftolllike pages 8-9): Samik Chakraborty, Juan Ye, Herui Wang, Mitchell Y Sun, Yaping Zhang, Xueyu Sang, and Zhengping Zhuang. Application of toll-like receptors (tlrs) and their agonists in cancer vaccines and immunotherapy. Frontiers in Immunology, Oct 2023. URL: https://doi.org/10.3389/fimmu.2023.1227833, doi:10.3389/fimmu.2023.1227833. This article has 108 citations and is from a peer-reviewed journal.
(jovasevic2024formationofmemory pages 1-2): Vladimir Jovasevic, Elizabeth M. Wood, Ana Cicvaric, Hui Zhang, Zorica Petrovic, Anna Carboncino, Kendra K. Parker, Thomas E. Bassett, Maria Moltesen, Naoki Yamawaki, Hande Login, Joanna Kalucka, Farahnaz Sananbenesi, Xusheng Zhang, Andre Fischer, and Jelena Radulovic. Formation of memory assemblies through the dna-sensing tlr9 pathway. Nature, 628:145-153, Mar 2024. URL: https://doi.org/10.1038/s41586-024-07220-7, doi:10.1038/s41586-024-07220-7. This article has 122 citations and is from a highest quality peer-reviewed journal.